Detalhe da pesquisa
1.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
2.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Future Oncol
; 19(1): 7-17, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779512
3.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069
4.
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Blood
; 123(18): 2895-7, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24786458
5.
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.
Onco Targets Ther
; 7: 245-51, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24611017
6.
Predicting benefit from imatinib: are we close?
Leuk Lymphoma
; 55(11): 2421-2, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24684225